Drug Profile
Research programme: ligand-conjugated antisense-based therapeutics - Ionis Pharmaceuticals
Alternative Names: ISIS TMPR SS6 LRx; ISIS-ANGPTL3LRxLatest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antisense oligonucleotides
- Mechanism of Action ANGPTL3 protein inhibitors; Apolipoprotein A inhibitors; Apolipoprotein C-III inhibitors; RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Beta-thalassaemia; Dyslipidaemias; Hyperlipoproteinaemia; Hypertriglyceridaemia; Resistant hypertension
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for preclinical development in Beta-thalassaemia in USA
- 28 Jan 2019 No recent reports of development identified for preclinical development in Dyslipidaemias in USA
- 28 Jan 2019 No recent reports of development identified for preclinical development in Hyperlipoproteinaemia in USA